---

Postmenopausal Bleeding (PMB)

Definition

---

Causes and Their Frequency

• Atrophic vaginitis / endometrial atrophy: Most common cause. Thinning of the endometrial lining and vaginal tissue due to estrogen deficiency. Women with atrophy have typically been menopausal for ~10 years. Endometrial biopsy often yields only blood and mucus, and bleeding usually ceases after biopsy.
• Endometrial polyps: Account for 2-12% of PMB. These are overgrowths of endometrial glands and stroma. The majority are benign, but up to 5% can undergo malignant transformation. Risk factors include increasing age, menopausal status, tamoxifen use, obesity, hypertension, and PCOS.
• Exogenous estrogen: A well-established risk factor. Unopposed estrogen therapy increases endometrial cancer risk 4-8x. Adding a progestin significantly reduces this risk.
• Endometrial hyperplasia: Occurs in 5-10% of PMB cases. Sources of excess estrogen include obesity, exogenous estrogen, or an estrogen-secreting ovarian tumor.
• Endometrial cancer: Present in approximately 10% of PMB cases. Postmenopausal bleeding is the most common presentation of endometrial cancer, and it permits early-stage diagnosis in many cases.
• Uterine leiomyomas (fibroids): Should never be accepted as a cause of PMB - another source must always be excluded.

Non-uterine causes to consider

• Urinary tract sources (hematuria)
• Gastrointestinal bleeding
• Cervical, vaginal, or vulvar lesions (usually evident on exam and require biopsy)
• Traumatic bleeding from an atrophic vagina (accounts for up to 15% of PMB, but uterine cause must first be excluded)
• Functional ovarian tumors producing estrogen

---

Evaluation

History and Examination

• Thorough history: bleeding pattern, duration, hormone use, medications (especially tamoxifen, anticoagulants), family history
• Pelvic examination: detect local lesions (cervix, vagina, vulva)
• Pap smear (cervical cytology)

Transvaginal Ultrasound (TVUS) - First-line imaging

• ≤4 mm: Low risk for endometrial cancer; endometrial biopsy may be avoided
• >4 mm: Endometrial biopsy is indicated
• Some sources cite a cutoff of <5 mm (Berek & Novak) or even 3 mm as more accurate

Important equity caveat: Recent data show that using a 4 mm cutoff alone may lead to under-diagnosing endometrial cancer in Black patients, and endometrial biopsy should have a lower threshold in this population. (Sabiston Textbook of Surgery, 11th ed.)

Endometrial Biopsy (EMB)

• Office endometrial biopsy is an excellent diagnostic test
• Indicated when:
  • Endometrial thickness >4 mm
  • Suspected focal lesion on imaging
  • Difficult visualization of endometrium
  • Persistent bleeding despite normal ultrasound
  • Cervical stenosis preventing ultrasound assessment
• Limitation: Can miss focal lesions (polyps); if sampling is inadequate, proceed to hysteroscopy

Hysteroscopy + D&C

• Gold standard for visualizing the endometrial cavity
• Particularly useful when polyps are suspected (difficult to detect with biopsy alone)
• Indicated when office biopsy is non-diagnostic or cervical stenosis precludes biopsy

Sonohysterography (Saline Infusion Sonography)

• Useful adjunct for identifying focal lesions (polyps, submucous fibroids)

---

Pathology: Endometrial Hyperplasia Classification

---

Management

Benign causes

• Atrophic vaginitis: Topical or systemic estrogen therapy after malignancy excluded. Vaginal routes (cream, tablet, ring) produce lower systemic levels.
• Cervical polyps: Removed in office
• Endometrial polyps: Hysteroscopic removal
• HRT-related: Regimen adjustment (add or increase progestin)

Endometrial Hyperplasia (EIN / Premalignant)

• Surgical (hysterectomy) is preferred
• Progestin therapy (oral, parenteral, or levonorgestrel IUD) for women who are poor operative candidates or desire fertility
• Follow-up endometrial biopsy every 3 months; recurrence risk approaches 50% with medical management

Endometrial Cancer

• Surgical staging (total hysterectomy + bilateral salpingo-oophorectomy + lymph node assessment) is the primary treatment
• Multidisciplinary review for adjuvant therapy planning
• Progestin therapy for women who are not surgical candidates

Acute Heavy Bleeding

• Unstable women with acute heavy vaginal bleeding: admit for IV estrogen therapy or surgical intervention

---

Risk Factors for Endometrial Cancer in PMB

• Obesity (unopposed peripheral estrogen from aromatization)
• Unopposed exogenous estrogen
• Late menopause, nulliparity
• Diabetes, hypertension
• Tamoxifen use
• Lynch syndrome / hereditary colorectal cancer syndromes
• Estrogen-secreting ovarian tumor

---

Key Take-Home Points

1. PMB = bleeding >12 months after last menstrual period. Always abnormal - always investigate.
2. Most common cause is atrophy (60-80%), but cancer must be excluded in every case.
3. ~10% of PMB is endometrial cancer; 90% of endometrial cancer presents with PMB.
4. Evaluation begins with TVUS: endometrial thickness ≤4 mm is reassuring; >4 mm warrants biopsy.
5. Endometrial biopsy remains the diagnostic cornerstone. Persistent bleeding with a normal ultrasound still warrants biopsy.
6. The 4 mm ultrasound threshold may miss cancer in Black patients - maintain a lower threshold for biopsy.
7. Uterine fibroids should never be accepted as the cause of PMB.
8. Polyps are often missed on blind biopsy - use hysteroscopy when bleeding persists.

---

---

Endometrial Cancer

Epidemiology

• ~67,000 new cases and ~13,000 deaths annually in the US
• Fourth most common cancer in women (after breast, lung, colorectal)
• ~3% of women will develop it in their lifetime
• Average age at diagnosis: 60 years; rare before age 45 (only 5% of cases are in women under 40)
• 75% of cases occur in women over 50
• More common in White women but has a higher mortality rate in Black women

---

Pathogenesis: Type I vs. Type II

Critical note: Serous and clear cell carcinomas make up less than 10% of endometrial cancers, yet account for more than half of all endometrial cancer deaths. - Berek & Novak's Gynecology

TCGA Molecular Subtypes (Modern Classification)

1. POLE ultra-mutated - best prognosis
2. Microsatellite instability (MSI) hypermutated - intermediate prognosis; ~30-40% of endometrioid cancers; responds to immunotherapy
3. Copy number low (TP53 wild-type)
4. Copy number high (TP53 mutated) - worst prognosis, behaves like serous tumors

---

Risk Factors

---

Genetic Syndromes

• Lynch syndrome (HNPCC): Most common hereditary cause (3-5% of endometrial cancers). Caused by germline mutations in DNA mismatch repair genes: MLH1, MSH2, MSH6, PMS2, or EPCAM. Up to 60% lifetime risk of endometrial cancer; average onset <45 years. All women diagnosed with endometrial cancer should undergo Lynch syndrome screening.
• Cowden syndrome: PTEN tumor suppressor gene mutation. 13-20% lifetime risk.

---

Clinical Features

Symptoms

• Abnormal vaginal bleeding or discharge in ~90% of cases - the primary presenting symptom
• Most women recognize the significance and seek consultation within 3 months
• Pelvic pressure / discomfort - suggests uterine enlargement or extrauterine spread
• Cervical stenosis can cause hematometra or pyometra (purulent discharge) - associated with poor prognosis
• Less than 5% are asymptomatic at diagnosis

Signs

• Uterine enlargement on pelvic exam (may be absent in early disease)
• Physical exam is often unremarkable in early-stage disease

---

Histological Subtypes

• Endometrioid adenocarcinoma: Most common (~80%). Well-differentiated glandular pattern
• Mucinous carcinoma: Similar behavior to endometrioid
• Serous carcinoma: Aggressive, spreads early even without deep myometrial invasion
• Clear cell carcinoma: Aggressive; characterized by clear and eosinophilic cells
• Carcinosarcoma (MMMT): Biphasic, contains malignant epithelial AND mesenchymal elements; TP53 mutations common; ~1/3 present with disease beyond uterus

---

Diagnosis and Pre-treatment Evaluation

Step-by-step workup

1. Pelvic examination - assess uterine size, adnexal masses, cervical involvement
2. Endometrial biopsy (office aspiration) - first and essential step; sensitivity ~90%
3. Transvaginal ultrasound (TVUS): Endometrial thickness >4-5 mm is suspicious; assess depth of myometrial invasion
4. Hysteroscopy + D&C: If office biopsy inadequate or non-diagnostic
5. MRI pelvis: Best modality for assessing depth of myometrial invasion and cervical involvement (pre-surgical staging)
6. CT chest/abdomen/pelvis: Evaluate for lymph node metastasis and distant spread
7. Pap smear: Sometimes shows abnormal endometrial cells

Screening

---

FIGO Staging and Treatment

---

Surgical Treatment

• Total hysterectomy + bilateral salpingo-oophorectomy (TH + BSO) is the cornerstone of treatment
• Minimally invasive surgery (laparoscopic or robotic) has largely replaced open surgery for uterine-confined disease
• Peritoneal washings and lymph node assessment are standard
• Sentinel lymph node biopsy is an acceptable alternative to full lymphadenectomy at experienced centers
• Visual inspection of upper abdomen to exclude extrauterine spread
• Full pathologic assessment: histologic subtype, grade, tumor size, depth of invasion, cervical involvement, lymphovascular space invasion (LVSI)

Fertility-Preserving Management

• Continuous progestin-based therapy (oral megestrol or levonorgestrel IUD)
• Repeat endometrial sampling every 3-6 months
• A 2024 systematic review (PMID 39032722) confirms this is an option for carefully selected Stage IA patients

---

Adjuvant Therapy

Radiotherapy

• Vaginal brachytherapy (VBT): Reduces vaginal recurrence in intermediate-risk Stage I disease
• External beam radiotherapy (EBRT): For cervical involvement (Stage II) and Stage III disease
• Isolated vaginal recurrences can be salvaged by radiotherapy in up to 80% of patients

Chemotherapy

• Used for advanced-stage (III-IV) and high-risk histologies
• Standard regimen: carboplatin + paclitaxel
• Systemic therapy is strongly recommended for FIGO Stage III-IVA disease of any histology

Immunotherapy (emerging / current standard for MMR-deficient tumors)

• Pembrolizumab (PD-1 inhibitor): FDA-approved for MSI-high/MMR-deficient endometrial cancer
• Dostarlimab: Also active in MMR-deficient tumors
• MSI/MMR-deficient tumors respond exceptionally well to checkpoint inhibitors due to high mutational burden
• The NCCN Guidelines Version 3.2025 (PMID 40763788) incorporate updates on the FIGO 2023 staging and new systemic therapy recommendations

Hormonal Therapy

• Progestins: For recurrent disease or fertility-sparing cases; response rates ~25% in advanced disease
• Best response in well-differentiated, ER/PR-positive tumors

---

Prognostic Variables

1. Advancing patient age
2. Non-endometrioid or Grade 3 histology
3. Deep myometrial invasion (≥50%)
4. Lymphovascular space invasion (LVSI)
5. Large tumor size
6. Cervical extension
7. Lymph node metastasis
8. Intraperitoneal spread
9. Positive peritoneal cytology

---

Surveillance After Treatment

• Gynecologic exam every 3-6 months for 2-3 years, then annually
• CA-125 if elevated at diagnosis
• CT/PET for symptomatic recurrence
• Vaginal recurrences (most common site of recurrence) are treated with radiotherapy with good salvage rates

---

Key Take-Home Points

1. Endometrial cancer is the most common gynecologic malignancy in developed countries
2. Postmenopausal bleeding is the hallmark symptom; 90% present this way, enabling early diagnosis
3. Type I (endometrioid, estrogen-related) has a favorable prognosis; Type II (serous/clear cell) is aggressive
4. Lynch syndrome is the most important hereditary association - screen all patients
5. Surgery (TH + BSO) is the primary treatment; minimally invasive approach preferred
6. MMR deficiency / MSI-high status guides immunotherapy eligibility - test all patients
7. Adjuvant therapy is guided by surgical stage and histological risk factors
8. Isolated vaginal recurrences are potentially curable with radiotherapy (~80% salvage)

---

---

Differential Diagnosis of Postmenopausal Bleeding

---

Overview by Frequency

---

Category 1: Non-Genital Tract Sources

Urinary Tract

• Hematuria - cystitis, urethritis, bladder cancer, urethral caruncle
• Urethral caruncle: a benign red, fleshy protrusion at the urethral meatus, common in postmenopausal women due to estrogen deficiency; often mistaken for vaginal bleeding
• Testing: urinalysis, urine culture, cystoscopy if indicated

Gastrointestinal Tract

• Rectal bleeding - hemorrhoids, colorectal cancer, diverticular disease, anal fissure
• Elderly patients may not accurately localize the source between the bladder, uterus, and rectum
• Testing: stool occult blood, proctoscopy, colonoscopy

---

Category 2: Vulvar and Vaginal Causes

Atrophic Vaginitis (Genitourinary Syndrome of Menopause)

• Most common non-uterine genital cause - accounts for up to 15% of all PMB
• Mechanism: estrogen deficiency causes thinning, dryness, and friability of the vaginal and vulvar epithelium; minor trauma causes bleeding
• Examination: thin, pale, friable vaginal mucosa with loss of rugae; reduced vaginal caliber
• Diagnosis of exclusion: a uterine source must be excluded before attributing bleeding to atrophy
• Treatment: topical or systemic estrogen

Vaginal Lesions

• Vaginal carcinoma (primary or metastatic): usually squamous cell; associated with HPV; presents as a visible vaginal wall lesion - requires biopsy
• Vaginal intraepithelial neoplasia (VAIN): premalignant; detected on colposcopy
• Vaginal trauma: from pessary use, douching, or intercourse in an atrophic vagina
• Vaginal polyps: benign, but must be distinguished from malignant lesions

Vulvar Lesions

• Vulvar carcinoma: squamous cell most common; visible ulcer, plaque, or mass on exam; biopsy required
• Lichen sclerosus: chronic inflammatory condition causing white plaques, thinning, and architectural destruction; may bleed with minor trauma; pre-malignant potential
• Lichen planus / contact dermatitis: inflammatory causes of vulvar bleeding

---

Category 3: Cervical Causes

Benign

• Cervical polyps: benign pedunculated outgrowths from the endocervical canal; can bleed with minimal contact; easily removed in office; endometrial biopsy still needed to exclude uterine source
• Cervical ectropion: uncommon postmenopausally (usually regresses)
• Cervicitis: uncommon postmenopausally but possible with atrophic changes or retained pessary

Malignant / Premalignant

• Cervical carcinoma: squamous cell (~80%) or adenocarcinoma (~20%); grossly visible lesion (friable, bleeding mass or ulcer) on speculum exam in most cases; diagnosed by biopsy; Pap smear may be abnormal
• Cervical intraepithelial neoplasia (CIN 3): premalignant; identified on colposcopy and biopsy

---

Category 4: Uterine / Endometrial Causes

Atrophic Endometrium (Most Common)

• Endometrial atrophy: accounts for 60-80% of all PMB; the endometrium thins due to estrogen withdrawal
• Mechanism: fragile, attenuated endometrium bleeds spontaneously or with minor stimulation
• TVUS: very thin endometrial stripe (<4 mm); biopsy yields scant tissue or blood and mucus
• Bleeding usually ceases after biopsy
• Women typically menopausal for ~10 years before presenting

Endometrial Polyps

• Account for 2-12% of PMB
• Benign overgrowths of endometrial glands and stroma (sessile or pedunculated)
• Up to 5% may undergo malignant transformation
• Often missed on blind endometrial biopsy - diagnosed best by hysteroscopy or sonohysterography
• Risk factors: increasing age, menopause, tamoxifen use, obesity, hypertension, PCOS
• Undetected polyps are a common cause of recurrent/persistent PMB

Endometrial Hyperplasia / EIN

• Accounts for 5-10% of PMB
• Benign endometrial hyperplasia: excess estrogen stimulation; treated medically with progestins
• Endometrial intraepithelial neoplasia (EIN): premalignant; ~30-fold risk of progressing to carcinoma; treated surgically (hysterectomy preferred) or with progestins if surgery is contraindicated
• Sources of excess estrogen: obesity (peripheral aromatization), unopposed HRT, estrogen-secreting ovarian tumor

Endometrial Cancer

• Accounts for ~10% of PMB - present in every case until excluded
• The most important diagnosis not to miss
• Type I (endometrioid): estrogen-related, better prognosis
• Type II (serous, clear cell, carcinosarcoma): estrogen-independent, aggressive
• Risk factors: obesity, nulliparity, unopposed estrogen, late menopause, DM, Lynch syndrome, tamoxifen

Uterine Leiomyoma (Fibroids)

• Important: fibroids should NEVER be accepted as a cause of PMB - they typically regress after menopause and another cause must always be excluded
• Rarely, submucosal fibroids may contribute to bleeding if still present and growing
• Rapid growth or growth after menopause raises suspicion for leiomyosarcoma

Uterine Sarcoma

• Rare but aggressive
• Leiomyosarcoma, endometrial stromal sarcoma, carcinosarcoma (MMMT)
• Suspect when fibroids appear to grow rapidly after menopause

Endometritis

• Chronic endometritis can cause irregular bleeding; may be associated with retained tissue or instrumentation
• Pyometra (pus in the uterus) may be associated with cervical stenosis; purulent discharge + bleeding; poor prognostic sign when associated with endometrial cancer

Intrauterine Adhesions / Hematometra

• Cervical stenosis can obstruct blood, causing hematometra
• Usually presents as cyclic pelvic pain without external bleeding, but can present with purulent discharge

---

Category 5: Ovarian / Adnexal Causes

• Estrogen-secreting ovarian tumors (granulosa cell tumor, thecoma): rare but important; produce excess estrogen leading to endometrial stimulation, hyperplasia, and bleeding
• Bilateral ovarian enlargement or pelvic mass on examination / TVUS
• Evaluate: pelvic TVUS, serum estradiol, inhibin levels (granulosa cell tumor marker)

---

Category 6: Iatrogenic / Drug-Related Causes

---

Summary Framework: Anatomical Approach

NON-GENITAL
├── Urinary: hematuria, urethral caruncle
└── GI: rectal bleeding

VULVA / VAGINA
├── Atrophic vaginitis ← most common non-uterine cause
├── Vaginal / vulvar carcinoma
├── Lichen sclerosus
└── Trauma (pessary, intercourse)

CERVIX
├── Cervical polyp
└── Cervical carcinoma

UTERUS ← most clinically critical zone
├── Endometrial atrophy ← most common overall (60-80%)
├── Endometrial polyp (2-12%)
├── Endometrial hyperplasia / EIN (5-10%)
├── Endometrial cancer (~10%) ← must exclude in ALL cases
├── Uterine sarcoma (rare)
└── Endometritis / pyometra

OVARY
└── Estrogen-secreting tumor (granulosa cell, thecoma)

IATROGENIC
├── HRT (unopposed estrogen or breakthrough on combined)
└── Tamoxifen, anticoagulants

---

Key Diagnostic Principles

1. Any PMB = abnormal until proven otherwise. Severity does not correlate with risk of malignancy.
2. Atrophy is the most common cause but is a diagnosis of exclusion - endometrial cancer must first be ruled out.
3. Uterine fibroids should never be accepted as the explanation for PMB.
4. Cervical and vaginal/vulvar lesions are usually visible on speculum exam - examine carefully before attributing bleeding to a uterine source.
5. Elderly patients may not accurately localize pain or bleeding between the bladder, uterus, and rectum - always perform a full pelvic exam.
6. Tamoxifen is a particularly important iatrogenic cause, as it thickens the endometrium paradoxically and increases polyp/hyperplasia/cancer risk despite being an anti-estrogen at the breast.
7. Estrogen-secreting ovarian tumors must be considered, especially when TVUS shows a thickened endometrium without an obvious intrauterine lesion.

---